Acetaminophen (APAP) is the leading cause of acute liver failure (ALF) in the United States, accounting for ~100,000 poison center calls, 50,000 ED visits, and at least 500 deaths annually. [1] Toxicity is dose-dependent, mediated by the toxic metabolite NAPQI when glutathione stores are overwhelmed. [2]
1. History
- Dose: Total amount ingested, mg/kg calculation; single time-point vs. repeated supratherapeutic ingestion (>24 hours) [3]
- Time of ingestion: Critical for nomogram use — must be established as precisely as possible; if unreliable, treat as unknown [3]
- Formulation: Immediate-release vs. extended-release (8-hour dosing products); combination products (opioid-APAP, diphenhydramine-APAP) [3]
- Intent: Intentional (self-harm) vs. unintentional ("therapeutic misadventure" — multiple APAP-containing products, chronic pain, flu-like illness) [1]
- Coingestants: Diphenhydramine, opioids, alcohol, other sedatives — affects clinical presentation and management [1]
- Symptom timeline: Nausea, vomiting, diaphoresis, malaise typically begin within 7–14 hours; may resolve by 24–48 hours creating a deceptive "honeymoon" period before hepatotoxicity peaks at 72–96 hours [4-5]
2. Alarm Features
- Altered mental status / encephalopathy — once present, ~1/3 of patients die or require liver transplant [1]
- Metabolic acidosis (arterial pH <7.3 after resuscitation) — King's College Criteria poor prognosis marker [6]
- Hyperlactatemia — suggests mitochondrial dysfunction, especially in high-risk ingestions (≥30 g) [3]
- INR >6.5 combined with creatinine >3.4 mg/dL and grade III–IV encephalopathy [6]
- Hypoglycemia — indicates severe hepatic synthetic failure [4]
- Massive ingestion (≥30 g or above the high-risk nomogram line) — warrants toxicology consultation and potentially increased NAC dosing [3]
3. Medications
- N-Acetylcysteine (NAC) — the only effective antidote; replenishes glutathione stores [1-2]
- IV protocol (preferred): 150 mg/kg load over 15–60 min → 50 mg/kg over 4 h → 100 mg/kg over 16 h (total 300 mg/kg over ~21 h) [1][7]
- Oral protocol: 140 mg/kg load → 70 mg/kg q4h for 17 additional doses (72 h total); antiemetics as needed [1]
- Key pearl: Do NOT stop NAC after a fixed 20–21 h — continue until stopping criteria are met: APAP level <10 µg/mL, INR normalizing, ALT improving/normal, patient clinically well [3]
- Activated charcoal: 1 g/kg (max 50 g) if within 4 hours of ingestion; may be useful beyond 4 h in high-risk or extended-release ingestions [2-3]
- Anaphylactoid reactions to IV NAC: Flushing, urticaria, bronchospasm — manage with antihistamines, slowing infusion rate; do not discontinue NAC [8]
- Fomepizole: Emerging adjunct in high-risk ingestions — consult toxicology [3]
- Medications that increase risk: CYP450 inducers (isoniazid, rifampin, phenytoin, carbamazepine, chronic alcohol) enhance NAPQI production [1]
The following figure from the 2023 US/Canada Consensus Statement illustrates the NAC administration algorithm with codified stopping criteria: [3]
4. Diet
- Fasting and malnutrition deplete intrahepatic glutathione stores, increasing susceptibility to toxicity even at therapeutic doses [1-2]
- Chronic alcohol use induces CYP2E1, increasing NAPQI production — though acute co-ingestion with overdose may paradoxically be hepatoprotective by competing for CYP metabolism [5]
- NPO status in the acute setting if vomiting or altered mental status; advance diet as tolerated once NAC is completed and liver function is improving
5. Review of Systems
- GI: Nausea, vomiting, anorexia, abdominal pain (especially RUQ — suggests hepatic injury)
- Neuro: Confusion, somnolence, asterixis (encephalopathy — late and ominous)
- Renal: Decreased urine output (renal tubular necrosis occurs in ~25% of severe cases) [4]
- Heme: Easy bruising, bleeding (coagulopathy)
- Psych: Suicidal ideation, depression — critical to assess in intentional ingestions
- Constitutional: Diaphoresis, malaise, pallor
6. Collateral History and Family History
- Collateral: Pill counts, empty bottles, pharmacy records, time witnesses last saw patient well, suicide note, prior attempts
- Medication access: Other household medications (coingestants), multiple APAP-containing products in the home
- Psychiatric history: Prior self-harm, depression, substance use
- Family history: Generally not contributory to acute toxicity, but family history of liver disease may affect baseline hepatic reserve
7. Risk Factors
- Dose >150 mg/kg (single acute ingestion) or >4 g/day (repeated supratherapeutic) [1]
- Chronic alcohol use — CYP2E1 induction [1]
- Fasting, malnutrition, anorexia — glutathione depletion [1-2]
- CYP450-inducing medications (isoniazid, anticonvulsants, rifampin) [1]
- Use of multiple APAP-containing products simultaneously [1]
- Hepatic impairment or active liver disease [4]
- Age — older adults have higher risk of severe outcomes; children <6 years tend to have less hepatotoxicity [5][9]
- Delayed presentation (>8 hours post-ingestion) — NAC efficacy diminishes progressively [7]
8. Differential Diagnosis
- Other toxic ingestions: Amanita phalloides (mushroom poisoning), carbon tetrachloride, other hepatotoxins
- Hepatic ischemia / shock liver: Hypotension-related — towering transaminases with low bilirubin can mimic APAP toxicity [1]
- Acute viral hepatitis: Hepatitis A, B, E — check serologies [1]
- Alcoholic hepatitis: Usually AST:ALT ratio >2:1, AST rarely >500
- Other drug-induced liver injury: Idiosyncratic DILI (e.g., isoniazid, statins)
- Budd-Chiari syndrome: Acute hepatic vein thrombosis
- Wilson disease: Acute presentation with hemolytic anemia, low ceruloplasmin
- Autoimmune hepatitis: Acute flare
- HELLP syndrome / acute fatty liver of pregnancy: In pregnant patients
Pearl: The classic APAP toxicity lab pattern — towering transaminases (often >3,000 U/L) with relatively low bilirubin (<10 mg/dL) — helps distinguish from other causes of ALF. [2]
9. Past Medical History
- Prior APAP overdose or self-harm attempts
- Chronic liver disease (reduced hepatic reserve)
- Alcohol use disorder
- Chronic pain conditions (risk for unintentional supratherapeutic use)
- Eating disorders / malnutrition
- Psychiatric diagnoses
- Renal impairment (CrCl ≤30 mL/min — increased caution) [4]
10. Physical Exam
- Vitals: Often normal early; tachycardia and hypotension are late/ominous signs suggesting hepatic failure or sepsis
- Abdomen: RUQ tenderness (hepatomegaly, hepatic capsular distension) — may be absent early
- Neuro: Mental status assessment — asterixis, confusion, coma indicate encephalopathy
- Skin: Jaundice (typically late, >72 h); diaphoresis early
- Stigmata of liver failure: Ascites, spider angiomata (unlikely in acute setting without pre-existing liver disease)
- Signs of coingestant toxicity: Miosis (opioids), anticholinergic toxidrome (diphenhydramine), sedation (barbiturates)
11. Lab Studies
- Serum acetaminophen level: Draw at ≥4 hours post-ingestion; plot on Rumack-Matthew nomogram [4][7]
- AST/ALT: Repeat q12–24h; ALT >1,000 IU/L is characteristic; may exceed 10,000–20,000 [2][5]
- INR/PT: Most important prognostic marker — prolonged INR is a bad sign [1]
- BMP: Creatinine (renal tubular necrosis), glucose (hypoglycemia), electrolytes, bicarbonate
- Total bilirubin: Characteristically low (<10 mg/dL) relative to transaminase elevation [1]
- Lactate: Elevated suggests mitochondrial dysfunction / poor prognosis [3][6]
- ABG/VBG: pH <7.3 after resuscitation = King's College poor prognosis criterion [6]
- Lipase: If abdominal pain, to exclude pancreatitis
- CBC: Thrombocytopenia may occur [4]
- Pregnancy test: In women of childbearing age [10]
- Salicylate level and toxicology screen: Especially in intentional ingestions [10]
- Hepatitis serologies: To exclude viral hepatitis [1]
- For repeated supratherapeutic ingestion: APAP level >20 µg/mL or abnormal AST/ALT → start NAC [3]
12. Imaging
- Imaging is generally not required for straightforward APAP toxicity
- RUQ ultrasound: Consider if diagnostic uncertainty (Budd-Chiari, biliary obstruction) or to assess hepatic vasculature
- CT abdomen: Not routinely indicated; may show hepatic edema/necrosis in severe cases
- CT head: If altered mental status to exclude intracranial pathology, especially with coingestants or trauma
- Chest X-ray: If aspiration risk (vomiting, altered consciousness) or hypoxia
13. Special Tests
- Rumack-Matthew Nomogram: Plot serum APAP level (drawn ≥4 h post-ingestion) vs. time — treatment line starts at 150 µg/mL at 4 hours (US); valid only for acute ingestions within 24 hours [4][8][11]
- King's College Criteria (APAP-specific poor prognosis): Arterial pH <7.3 after resuscitation, OR all three of: INR >6.5, creatinine >3.4 mg/dL (>300 µmol/L), and grade III–IV encephalopathy [6]
- APAP-protein adducts: Emerging biomarker for confirming APAP toxicity when level is undetectable (not yet commercially available) [2]
- ALFSG Prognostic Index: Coma grade, etiology, vasopressor use, INR, bilirubin — predicts transplant-free survival [12]
The following figure shows the King's College Criteria for liver transplant listing in ALF: [13]
14. ECG
- APAP itself does not typically cause primary ECG abnormalities
- ECG is indicated to evaluate for coingestant toxicity: QRS prolongation (TCAs), QTc prolongation (diphenhydramine, other agents), AV block (beta-blockers, calcium channel blockers) [10]
- Rare reports of myocardial ischemia and ST changes in massive overdose, possibly from oxidative stress and sulphydryl depletion [14-15]
- Bradycardia has been associated with worse outcomes in large cohort data [9]
- Telemetry monitoring recommended during IV NAC infusion (anaphylactoid risk) [1]
15. Assessment
Four clinical stages of APAP toxicity: [5][16]
Prognosis is related to the degree of encephalopathy, coagulopathy, and acidosis. [1] APAP-induced ALF carries ~28% mortality; up to 1/3 require liver transplant. [2] However, if NAC is given within 12 hours, liver damage is virtually assured to be minimal. [1]
16. Treatment Plan
Initial stabilization
- ABCs, IV access, cardiac monitoring
- Assess airway — intubate if GCS ≤8 or unable to protect airway
GI decontamination
Antidote — NAC
- Start immediately if: APAP level above treatment line on nomogram, time of ingestion unknown, or clinical/lab evidence of toxicity [2-3]
- IV NAC (preferred): 150 mg/kg over 15–60 min → 50 mg/kg over 4 h → 100 mg/kg over 16 h [1][7]
- Oral NAC: 140 mg/kg load → 70 mg/kg q4h × 17 doses [1]
- Stopping criteria: APAP <10 µg/mL, INR normalizing (<2), ALT improving, clinically well [3]
- If liver injury present, extend NAC at 6.25 mg/kg/h until ALT decreasing and INR <2 [1]
High-risk ingestion (≥30 g)
- Consider increased NAC dosing in consultation with toxicology [3]
- Additional labs: lactate, blood gas [3]
- Consider fomepizole as adjunct [3]
Supportive care
- Correct hypoglycemia (D10 or D50 infusion)
- Correct coagulopathy only if active bleeding (FFP/vitamin K — INR is a prognostic marker; correcting it obscures trajectory)
- Manage cerebral edema if encephalopathy progresses
17. Disposition
- Admit (medical floor or ICU): All patients receiving NAC, any evidence of liver injury, intentional ingestion pending psychiatric evaluation [10]
- ICU admission: Encephalopathy, coagulopathy (INR >2), metabolic acidosis, renal failure, hemodynamic instability [1]
- Liver transplant center referral: Any patient meeting or approaching King's College Criteria; encephalopathy + coagulopathy = prompt referral [1][17]
- Discharge considerations: APAP level below treatment line on nomogram (drawn ≥4 h post-ingestion), normal AST/ALT, no symptoms, reliable history, and psychiatric clearance if intentional [3]
- Psychiatric evaluation: Mandatory for all intentional ingestions before discharge [10]
- Poison Control: Contact at 1-800-222-1222 for guidance on any uncertain case [4]
18. Follow Up / Return Precautions
- Follow-up timing: Repeat LFTs at 24–48 hours post-discharge if any concern for delayed toxicity; PCP follow-up within 1–2 days
- Return immediately for: Recurrent vomiting, abdominal pain, jaundice, confusion, dark urine, easy bruising/bleeding
- Patient counseling:
- Maximum APAP dose: ≤4 g/day for healthy adults (≤2 g/day if chronic alcohol use or liver disease) [2]
- Awareness of APAP in combination products (Vicodin, Percocet, NyQuil, Excedrin, etc.)
- Avoid alcohol during recovery
- Expected recovery: Survivors of APAP hepatotoxicity typically make a full and complete recovery within 7 days with no chronic liver sequelae [1]
- Psychiatric follow-up: Ensure outpatient mental health follow-up and safety planning for intentional ingestions
References
1. AASLD Practice Guidance on Drug, Herbal, and Dietary Supplement-Induced Liver Injury. — Fontana RJ, Liou I, Reuben A, et al. Hepatology. 2023.
2. Acute Liver Failure Guidelines. — Shingina A, Mukhtar N, Wakim-Fleming J, et al. The American Journal of Gastroenterology. 2023.
3. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. — Dart RC, Mullins ME, Matoushek T, et al. JAMA Network Open. 2023.
4. FDA Drug Label. — Updated date: 2023-11-01. Food and Drug Administration.
5. Acetaminophen Overdose. — Rumack BH. The American Journal of Medicine. 1983.
6. Development and Validation of a Dynamic Outcome Prediction Model for Paracetamol-Induced Acute Liver Failure: A Cohort Study. — Bernal W, Wang Y, Maggs J, et al. The Lancet. Gastroenterology & Hepatology. 2016.
7. FDA Drug Label. — Updated date: 2026-05-06. Food and Drug Administration.
8. Fifty Years of Paracetamol (Acetaminophen) Poisoning: The Development of Risk Assessment and Treatment 1973-2023 With Particular Focus on Contributions Published From Edinburgh and Denver. — Bateman DN, Dart RC, Dear JW, Prescott LF, Rumack BH. Clinical Toxicology. 2024.
9. Prognostic Factors of Acetaminophen Exposure in the United States: An Analysis of 39,000 Patients. — Mehrpour O, Saeedi F, Hadianfar A, Mégarbane B, Hoyte C. Human & Experimental Toxicology. 2021.
10. Acute Medication Poisoning. — Vega IL, Griswold MK, Laskey D. American Family Physician. 2024.
11. Interventions for Paracetamol (Acetaminophen) Overdose. — Chiew AL, Gluud C, Brok J, Buckley NA. The Cochrane Database of Systematic Reviews. 2018.
12. Acute Liver Failure. — Maiwall R, Kulkarni AV, Arab JP, Piano S. Lancet. 2024.
13. Acute Liver Failure: Prognosis and Management. — Jennifer Price, Brian J. Hogan, Banwari Agarwal Evidence‐based Gastroenterology and Hepatology 4e. 2019.
14. Paracetamol Cardiotoxicity. — Armour A, Slater SD. Postgraduate Medical Journal. 1993.
15. Possible Fatal Acetaminophen Intoxication With Atypical Clinical Presentation. — De-Giorgio F, Lodise M, Chiarotti M, et al. Journal of Forensic Sciences. 2013.
16. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Diagnosis and Management of Pediatric Acute Liver Failure. — Squires JE, Alonso EM, Ibrahim SH, et al. Journal of Pediatric Gastroenterology and Nutrition. 2022.
17. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. — Martin P, DiMartini A, Feng S, Brown R, Fallon M. Hepatology. 2014.